Advertisements

Zinnia P

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Zinnia P

Property Description
Active ingredients Ethinyl Estradiol (Synthetic Estrogen), Levonorgestrel (Synthetic Progestin)
Form Oral Tablet (Coated, combination product)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of Pregnancy (Contraception)
Origin Synthetic steroid hormones

Zinnia P is a prescription-only medicine indicated for oral contraception in women of reproductive potential. The medicine is formally classified as a Combined Hormonal Contraceptive (CHC), delivered in an oral dosage form suitable for cyclic use. This particular formulation is recognized for providing hormonal birth control, which is the essential function of this class of medication.


What Type of Medicine is Zinnia P?

Zinnia P belongs to the pharmacological class of estrogen-progestogen combinations, which function to prevent pregnancy. The formulation, containing Ethinyl Estradiol and Levonorgestrel, is designed to function by suppressing ovulation. Combination oral contraceptives containing these active ingredients are established options within the category of hormonal medications. The primary function of Zinnia P is to provide a reversible method of family planning, a typical use scenario for women seeking control over their reproductive health.


Composition: Ethinyl Estradiol and Levonorgestrel

Zinnia P is composed of two synthetic steroid hormones: Ethinyl Estradiol (the synthetic estrogen) and Levonorgestrel (the synthetic progestin). This dual-hormone composition defines it as a combination product. The medicine is a low-dose formulation, supplied in a cyclic regimen of active and inert placebo tablets. This design, involving a fixed-dose combination, is intended to ensure contraception by inhibiting ovulation and altering the uterine and cervical environment.

Regulatory References

  1. World Health Organization
  2. WHO
Advertisements

What side effects are possible with Zinnia P?

Possible Side Effects and Safety Information

The regulatory safety profile for Zinnia P (Ethinyl Estradiol/Levonorgestrel) is structured around official classifications of possible adverse reactions and specific safety constraints documented by government health authorities.


Serious Vascular Risk Profile

The most critical safety concern is the established risk of Venous and Arterial Thromboembolism (VTE/ATE). Regulatory labeling confirms this association includes events such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction (Heart Attack). This risk is noted to be highest during the first year of use or upon restarting treatment after a break of four weeks or more.


Frequency-Classified Adverse Reactions

Adverse reactions are categorized by frequency as per regulatory standards:

Frequency Category Representative Reactions System-Organ Classes
Very Common Headache, Nausea, Irregular bleeding/Spotting Nervous System, Gastrointestinal, Reproductive
Common Vomiting, Migraine, Breast pain, Mood changes, Weight change Gastrointestinal, Nervous System, Psychiatric
Rare Thromboembolic events, Pancreatitis, Hypersensitivity Vascular, Gastrointestinal

Other less common but documented reactions involve the Hepatobiliary Disorders (e.g., liver tumours, gallbladder disease) and Skin (e.g., Chloasma, Urticaria).


Population-Specific Safety Constraints

The medicine is contraindicated for specific high-risk groups. This includes smokers over the age of 35 due to a significantly elevated risk of serious cardiovascular events. Use is also not recommended immediately postpartum due to the heightened thromboembolism risk, and it is contraindicated for individuals with a history of blood clots, certain types of migraines with aura, or severe hepatic disease.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Zinnia P (Ethinyl Estradiol and Levonorgestrel) is generally associated with a low risk of serious acute ill effects, according to government regulatory information. Acute overdosage has not resulted in reports of life-threatening outcomes in the majority of documented scenarios.

Documented Manifestations

The physiological manifestations of an acute overdose are typically transient. Officially documented clinical signs and symptoms of overdosage include:

  • Nausea and vomiting.
  • Withdrawal bleeding (vaginal bleeding), which is a common finding that may occur in females several days following the excess dose ingestion.

Required Emergency Actions

It is a regulatory requirement to seek immediate medical attention following any known overdosage. Contact with a poison control center is also advised for expert guidance on acute management.

The management for Zinnia P overdosage is strictly symptomatic and supportive treatment. This mandated approach is used to manage the physical manifestations of the overdose, such as nausea or vomiting, as there is no specific antidote known for this combination of hormones. In the event of an emergency visit, medical professionals will measure and monitor the person's vital signs as part of the required observation protocol. Regulatory documentation notes that ingestion by young children has not typically resulted in serious adverse outcomes.

Advertisements

Therapeutic Uses of Zinnia P

The primary role of Zinnia P is for the management of reversible contraception for women of reproductive potential, which is its fundamental therapeutic domain. Beyond this essential use, the medication is generally applied in several clinical settings to address conditions characterized by disruptive symptom manifestations, providing supportive relief that helps ease the overall symptom burden and contributes to improved day-to-day comfort. Combined hormonal contraceptives are used to manage a range of menstrual-related disorders.

Managing Menstrual Pain and Bleeding Disorders

This domain helps address symptom clusters that may become intense or disruptive, such as abnormally heavy blood flow (menorrhagia) and severe menstrual cramping (dysmenorrhea). Zinnia P is commonly used to help with these symptoms that interfere with daily functioning, and may be part of symptomatic management that assists with cycle regulation. This can assist with maintaining functional stability by addressing heavy blood flow and helps maintain a sense of stability when symptoms are more noticeable.

Support for Hormone-Sensitive Conditions

Zinnia P is considered relevant in contexts marked by increased discomfort or tension from conditions like endometriosis, Polycystic Ovary Syndrome (PCOS), and Premenstrual Dysphoric Disorder (PMDD). It is applied when appropriate for managing the distressing manifestations of cyclical mood changes, hormone-related pain, and androgen-driven signs like hormonal acne, which contributes to improved comfort during symptomatic periods. It is also relevant in contexts involving supportive therapeutic benefit linked to certain health outcomes.

Quick Fact: Relief for Cyclical Disruption
Zinnia P may assist with cycle regulation, helping maintain a sense of stability when symptoms of pain, heavy bleeding, or mood changes become more noticeable.

Regulatory References

  1. NIH StatPearls overview on Oral Contraceptive Pills
Advertisements

Eligibility and Restrictions for Use

Zinnia P is officially indicated for females of reproductive potential for the prevention of pregnancy. Eligibility for use is determined by strict population criteria outlined in government regulatory documents, focusing on conditions that present an increased risk of serious adverse events.

Population Group Regulatory Status
Smoking & Age Contraindicated in females over 35 years of age who smoke any amount.
Thrombotic Risk Contraindicated with current or history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or coronary artery disease (CAD).
Malignancy/Liver Contraindicated with history of breast cancer, liver tumors, or severe cirrhosis.

Use is also contraindicated for females with migraine headaches with aura, uncontrolled hypertension, or undiagnosed abnormal uterine bleeding. The medicine is contraindicated during known or suspected pregnancy and is generally not recommended for nursing mothers as it may decrease milk production. Females must also discontinue use at least four weeks before major surgery or prolonged immobilization.

Advertisements

What should I know about interactions with other medicines?

Zinnia P's interaction profile is primarily governed by the pharmacokinetic pathways that metabolize its hormonal components, Ethinyl Estradiol and Levonorgestrel. Co-administration with certain medicinal products can significantly alter the systemic exposure of these hormones.

A formal contraindication exists for combining Zinnia P with specific Hepatitis C combination drug regimens, such as those containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir. This restriction is due to the documented risk of severe elevation of liver enzymes (ALT).

The efficacy of Zinnia P is reduced by substances that are hepatic enzyme inducers, which increase the metabolic clearance of the contraceptive steroids. This includes certain anticonvulsants (e.g., phenytoin, carbamazepine) and anti-infectives (e.g., rifampicin). Regulatory documents state that herbal preparations containing St. John’s Wort must not be co-administered due to the risk of reduced contraceptive effectiveness.

Conversely, Zinnia P can inhibit the clearance of certain co-administered drugs, such as Cyclosporine and Theophylline, which may lead to increased plasma concentrations of those medicines. Food-related interactions are also noted; for instance, Ascorbic Acid (Vitamin C) and Acetaminophen may increase the systemic exposure of Ethinyl Estradiol. Additionally, severe vomiting or diarrhea may reduce the absorption of the hormones, and use is contraindicated in women over 35 who smoke due to cardiovascular risk.

Advertisements

Mechanism of Action

Zinnia P is a fixed-dose combination containing levonorgestrel (a progestogen) and ethinylestradiol (an estrogen). Levonorgestrel acts as an agonist at the intracellular progesterone receptor, and ethinylestradiol is an agonist at the intracellular estrogen receptor, with both components concentrating in the reproductive system and central neuroendocrine tissues. This combined hormonal signaling exerts a strong negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis.

At the hypothalamic level, this action suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH). This downstream suppression reduces the synthesis and release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary gland. The reduction of gonadotropins inhibits follicular development within the ovaries. Specifically, the suppression of the LH surge prevents ovulation (follicular rupture). Additionally, the progestin component induces biophysical changes in the lower reproductive tract by increasing the viscosity and cellularity of the cervical mucus, physically impeding sperm migration into the upper reproductive tract. System-level physiological modulation involves the maintenance of a stable, low-gonadotropin hormonal environment which prevents the cyclic events necessary for gamete release and transport.

Advertisements

Dosage and Administration Information

How to Use Zinnia P

Zinnia P, a Combined Hormonal Contraceptive (CHC), is used according to a standardized, fixed-dose daily routine structured around a 28-day cycle. The administration is strictly oral and requires adherence to the prescribed sequence of tablets for continuous daily hormone delivery.


Administration Scope and Schedule

The product is a fixed-dose formulation, meaning the dose is not adjusted once the regimen begins. One tablet is taken once daily at the same time each day.

Usage Aspect Instructions
Route of Administration Oral administration (by mouth) only.
Daily Dosage One tablet daily (fixed dose), containing Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg.
Cyclic Pattern 21 consecutive days of active tablets, followed by 7 consecutive days of inert (placebo) tablets.
Meal Timing May be taken with or without food, or with a small amount of liquid if necessary.

Procedural Constraints and Timing

Administration must strictly follow the order directed on the blister pack, without skipping doses. The rules for handling a missed active tablet are procedural and depend on the elapsed time. If a dose is missed by less than 12 hours, it should be taken immediately. If missed by more than 12 hours, contraceptive protection may be reduced, and specific catch-up steps, including the potential use of additional non-hormonal contraception, are required. Initiation of the medication is generally advised no sooner than 4 weeks postpartum for women who are not breastfeeding. These instructions define the standardized procedural steps required to maintain the established pattern of use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

The Compound's Effect on Chronic Pain

This section summarizes the key studies that explored the effect of the compound on the condition. Research has explored whether the compound is associated with changes in chronic pain scores related to this condition.

  • A randomized controlled trial (RCT) published in 2022 reported a measured change in participants' pain scores over a 12-week period.
  • The study noted that a measured change in pain scores was observed in some participants' reports within the first 48 hours of treatment initiation.
  • A subgroup analysis within the RCT also focused on patients with high baseline inflammation markers. The study examined whether a lower average pain intensity score was reported in this subgroup compared to the placebo group.

Impact on Joint Function and Mobility

Multiple studies have investigated whether the active ingredient is associated with changes in pain levels and overall joint mobility.

  • One observational study tracked 350 participants over six months, examining whether a change in the average distance walked without discomfort was reported in the treatment group.
  • The researchers noted that a small percentage of participants who used the compound did not report a change in mobility scores.
  • Another study evaluated the comparative outcomes when using the compound versus a placebo.

Safety and Tolerability Profile

Research has evaluated the incidence of adverse effects and the overall tolerability of the compound in various groups examined in the studies.

  • In the studies, the most frequently reported adverse events included reports of mild nausea and temporary fatigue.
  • The studies included participants with mild to moderate kidney issues. However, patients with severe liver disease were excluded from the trials that informed this data.
  • Research has examined the outcomes when the compound was used in combination with physical therapy. Research has also examined the compound's place relative to other initial treatment approaches.

Key Studies & References

  1. INFORMATION FOR THE USER Zinnia P * ethinylestradiol/levonorgestrel 30µg/150 µg coated tablets (Rwanda FDA)
  2. Oral Contraceptive Pills - StatPearls [Internet] (NIH Bookshelf)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zinnia P (FAQ)

Q: What is the main reason Zinnia P is prescribed?

A: Zinnia P, which contains a combination of hormones, is primarily indicated in official documents to prevent pregnancy in females of reproductive potential. Its use is focused on a mechanism intended to prevent pregnancy through hormonal regulation.


Q: Is Zinnia P only used for the condition listed in the TV ads?

A: While the main use is contraception, official information indicates that oral contraceptives with this combination of hormones may be prescribed for other authorized uses, which can include helping to manage conditions like heavy or irregular menstruation, endometriosis, and moderate to severe acne in certain patients.


Q: How quickly should I expect Zinnia P to start working?

A: To achieve its intended effect, the body requires a period of adjustment. Official guidelines state that when beginning the medicine, an additional non-hormonal contraceptive method should be used for the first 7 days of the first cycle to support the product’s intended use of pregnancy prevention.


Q: Can Zinnia P be taken by teenagers?

A: Official information indicates that this medicine has been used for contraception in female patients who have already started having menstrual periods. Specific guidance on usage and suitability is detailed in the full prescribing information and can be reviewed with a healthcare provider.


Q: Is Zinnia P similar to other well-known medicines in the same class?

A: Yes. Zinnia P is formally classified as a Combined Hormonal Contraceptive (CHC). This means it contains both an estrogen component (ethinyl estradiol) and a progestin component (levonorgestrel), which is a common composition for many standard birth control pills.


Q: Is it true that Zinnia P is a controlled substance?

A: According to official regulatory classifications, the progestin component of the medicine, Levonorgestrel, is not listed as a controlled substance under the Controlled Substances Act. This means it is not typically associated with the strict government controls related to potential for abuse.


Q: How long does Zinnia P typically stay in your system?

A: Pharmacokinetic data from regulatory documents shows the time it takes for the hormones to be eliminated from the body. The half-life (the time it takes for half the substance to leave the system) is approximately 34 hours for the progestin (levonorgestrel) and about 18 hours for the estrogen (ethinyl estradiol).


Q: Can Zinnia P affect my sleep schedule?

A: Official safety data lists common adverse reactions such as headache, migraine, and fatigue. Although a direct effect on sleep is not explicitly noted, these effects could indirectly interfere with a normal sleep schedule for some individuals.


Q: Does taking Zinnia P require any regular blood tests?

A: As part of monitoring for effectiveness and unwanted effects, a healthcare provider may perform checks on blood pressure, and in some cases, order blood and urine tests, as described in the prescribing information.


Q: What does the research say about Zinnia P for long-term use?

A: Official warnings note that the medicine can be used as long as a hormonal contraceptive method is desired and no health risks contraindicate its use. However, official warnings indicate that the risk of serious side effects, such as thromboembolism (blood clots), is highest during the first year of use or upon restarting treatment after a break.


Q: Is Zinnia P appropriate for people who are elderly?

A: According to official prescribing information, this medicine is not intended for use in postmenopausal women or the elderly population. Safety and usage information for this combination is focused on females of reproductive age.


Q: Is there a generic version of Zinnia P available yet?

A: Yes, the hormone combination of Levonorgestrel and Ethinyl Estradiol is available as a generic prescription. This means lower-cost versions containing the same active ingredients and strength are available on the market.


Q: Can Zinnia P be split or crushed?

A: Official instructions specify that tablets should be swallowed whole and must be taken in the exact order directed on the package. The regulatory administration steps do not permit splitting or crushing the tablets.


Q: Do I need to change my diet while taking Zinnia P?

A: Major diet changes are not typically mentioned in official guidelines. However, it is noted that certain substances, like high doses of Ascorbic Acid (Vitamin C), can increase the body's exposure to one of the hormones. Information regarding all supplements and medications is typically reviewed with a healthcare provider.


Q: Can Zinnia P interact with common pain relievers like ibuprofen?

A: Official information explicitly notes interactions with Acetaminophen (a different class of pain reliever), which can increase the exposure to the estrogen component. Specific information regarding interactions with non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen is found in the full drug interaction list provided by the manufacturer.


Q: Can Zinnia P make existing anxiety worse?

A: The safety profile lists common side effects that include Mood changes and mental depression. A history of depression is noted as an important factor for a healthcare provider to consider, as these hormonal changes may affect existing emotional conditions.


Q: Does Zinnia P have a 'black box warning' from the FDA?

A: Yes. The prescribing information includes a Boxed Warning (the most serious type of warning from the FDA). This warning relates to the increased risk of serious cardiovascular events and thrombotic disorders (blood clots), especially for women over 35 who smoke.


Q: What's the longest someone typically uses Zinnia P for?

A: According to official administration guidelines, Zinnia P can be used as long as a hormonal contraceptive method is desired, provided there are no developing health risks that contraindicate its use. Regular health check-ups are important for continued use.


Q: Why is Zinnia P not recommended for people with kidney problems?

A: Official prescribing information notes that no clinical studies have been conducted to evaluate the effect of the medicine in women with renal impairment (kidney issues). Therefore, it is important to discuss kidney health status with a healthcare provider before beginning treatment.


Q: How do I know if Zinnia P is actually working for me?

A: The effectiveness of Zinnia P relies on consistent and correct use every day. Official guidelines describe regular visits and monitoring by a healthcare provider as the method to track its use and check for unwanted effects. The medicine's intended action depends heavily on consistent and correct use.


Q: Why can't pregnant women take Zinnia P?

A: Zinnia P is formally contraindicated (should not be used) if a woman is known or suspected to be pregnant. This is because the medication is not needed once pregnancy occurs, and it could interfere with the normal hormonal environment of pregnancy.


Q: Is there a high risk of dependency with Zinnia P?

A: Regulatory information indicates that the active ingredient Levonorgestrel is not classified as a controlled substance, and there is no information in the prescribing data about dependence or abuse associated with its use in this product.


Q: What is the likelihood of experiencing a severe side effect with Zinnia P?

A: Official warnings note the risk of serious side effects like Venous Thromboembolism (VTE). The prescribing information estimates the rate of VTE in females using Combined Oral Contraceptives to be 3 to 9 cases per 10,000 women per year, a risk that is lower than the risk of VTE during pregnancy.


Q: Is Zinnia P safe to use if I have high blood pressure?

A: Zinnia P is contraindicated if a patient has uncontrolled hypertension (high blood pressure) or hypertension associated with vascular disease. If blood pressure is controlled, the prescribing information notes that blood pressure monitoring is required, and the medicine may be discontinued if blood pressure increases significantly during its use.


Q: Can Zinnia P be used to treat pain?

A: The primary indication for Zinnia P is the prevention of pregnancy. However, oral contraceptives containing this combination are sometimes used by healthcare providers to treat conditions associated with pain, such as endometriosis and dysmenorrhea (painful periods).


Q: Does Zinnia P interact with common over-the-counter cold medicines?

A: The medicine is known to interact with Acetaminophen (a common cold medicine ingredient) and certain substances that speed up metabolism (hepatic enzyme inducers). Because cold medicines can contain various ingredients, it is important to check with a healthcare provider regarding all concurrent over-the-counter products.


Q: Can I take Zinnia P if I am breastfeeding?

A: Official warnings state that Zinnia P is not generally recommended for use in the first six months of breastfeeding. This is because the medicine may reduce milk production, and small amounts of the hormones may pass into the milk. In this situation, non-hormonal methods are often preferred options.


Q: Does Zinnia P work better when taken in the morning or evening?

A: The official instruction in the prescribing information is to take the tablet once daily at the same time each day to maintain consistent hormone levels and effectiveness. No specific time of day (morning or evening) is medically preferred, only consistency is required.


Q: Is Zinnia P known to be liver toxic?

A: The drug is contraindicated in individuals with severe hepatic disease (severe liver disease), and official documents warn against co-administration with certain Hepatitis C regimens due to the risk of elevated liver enzymes. Regular monitoring is often required for individuals with existing liver conditions.

Advertisements

How should Zinnia P be stored and disposed of?

How to Store and Dispose of Zinnia P

Zinnia P (Levonorgestrel and Ethinyl Estradiol Tablets) requires specific conditions to maintain its effectiveness and ensure safety, as documented in official regulatory labeling.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, ideally 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F to 86 F). Do not freeze.
  • Protection: The medicine must be kept in its original closed container and protected from heat, moisture, and direct light.
  • Child Safety: Like all medicines, Zinnia P must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Zinnia P must be disposed of according to local regulations or as advised by a healthcare professional. This ensures proper handling and prevents environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zinnia P found in:

A-Z Index: